A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.

被引：2
|
作者：
Yamada, Kazuhiko
Miyamoto, Shingo
Azuma, Koichi
Ishii, Hidenobu
Bessho, Akihiro
Fukamatsu, Nobuaki
Kunitoh, Hideo
Ishii, Mari
Tanaka, Hiroshi
Aono, Hiromi
Nakahara, Yoshiro
Kusaka, Kei
Hosomi, Yukio
Kikuchi, Norihiro
Mori, Yoshiaki
Itani, Hidetoshi
Kasai, Takashi
Ichiki, Masao
Seki, Nobuhiko
Okamoto, Hiroaki
机构：
[1] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan
[2] Japanese Red Cross Med Ctr, Tokyo, Japan
[3] Japanese Red Cross Okayama Hosp, Okayama, Japan
[4] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan
[5] Niigata Canc Ctr Hosp, Dept Resp Med, Niigata, Japan
[6] Mitsui Mem Hosp, Tokyo, Japan
[7] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[8] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan
[9] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[10] Kasumigaura Med Ctr, Tsuchiura, Ibaraki, Japan
[11] Iwate Cent Prefectural Hosp, Morioka, Iwate, Japan
[12] Japanese Red Cross Ise Hosp, Ise, Japan
[13] Tochigi Canc Ctr, Dept Resp Med, Utsunomiya, Tochigi, Japan
[14] Kyushu Med Ctr, Fukuoka, Fukuoka, Japan
[15] Teikyo Univ, Sch Med, Tokyo, Japan
[16] Yokohama Municipal Citizens Hosp, Dept Resp Med & Med Oncol, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9063
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Multicenter Phase II Study of Low-Dose Erlotinib in Frail Patients with EGFR Mutation-Positive, Non-Small Cell Lung Cancer: TORG1425
    Otani, S.
    Yamada, K.
    Miyamoto, S.
    Azuma, K.
    Ishii, H.
    Bessho, A.
    Hosokawa, S.
    Kunitoh, H.
    Miyazaki, K.
    Tanaka, H.
    Miura, S.
    Aono, H.
    Nakahara, Y.
    Kusaka, K.
    Hosomi, Y.
    Hamada, A.
    Okamoto, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S338 - S338
  • [2] A phase II study of low-dose erlotinib in frail patients with EGFR-mutant non-small cell lung cancer: TORG1425
    Bessho, Akihiro
    Miyamoto, Shingo
    Azuma, Koichi
    Ishii, Hidenobu
    Hosokawa, Shinobu
    Kunitoh, Hideo
    Shimokawa, Tsuneo
    Tanaka, Hiroshi
    Aono, Hiromi
    Nakahara, Yoshiro
    Hosomi, Yukio
    Kusaka, Kei
    Yamada, Kazuhiko
    Okamoto, Hiroaki
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer A Multicenter Phase 2 Trial
    Miyamoto, Shingo
    Azuma, Koichi
    Ishii, Hidenobu
    Bessho, Akihiro
    Hosokawa, Shinobu
    Fukamatsu, Nobuaki
    Kunitoh, Hideo
    Ishii, Mari
    Tanaka, Hiroshi
    Aono, Hiromi
    Nakahara, Yoshiro
    Kusaka, Kei
    Hosomi, Yukio
    Kikuchi, Norihiro
    Mori, Yoshiaki
    Itani, Hidetoshi
    Hamada, Akinobu
    Yamada, Kazuhiko
    Okamoto, Hiroaki
    JAMA ONCOLOGY, 2020, 6 (07)
  • [4] A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632
    Noro, Rintaro
    Igawa, Satoshi
    Bessho, Akihiro
    Hirose, Takashi
    Shimokawa, Tsuneo
    Nakashima, Masanao
    Minato, Koichi
    Seki, Nobuhiko
    Tokito, Takaaki
    Harada, Toshiyuki
    Sasada, Shinji
    Miyamoto, Shingo
    Tanaka, Yosuke
    Furuya, Naoki
    Kaburagi, Takayuki
    Hayashi, Hideki
    Iihara, Hirotoshi
    Okamoto, Hiroaki
    Kubota, Kaoru
    LUNG CANCER, 2021, 161 : 49 - 54
  • [5] A PROSPECTIVE, MULTI-CENTER PHASE II TRIAL ON THE EFFICACY AND SAFETY OF LOW-DOSE ERLOTINIB MONOTHERAPY FOR PATIENTS WITH EGFR MUTATION-POSITIVE, PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER: RESULTS OF THORACIC ONCOLOGY RESEARCH GROUP (TORG) TRIAL 0911
    Yamada, Kazuhiko
    Kunitoh, Hideo
    Hosomi, Yukio
    Okamoto, Hiroaki
    Kato, Terufumi
    Komase, Yuko
    Nishikawa, Masanori
    Morita, Satoshi
    Watanabe, Koshiro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S600 - S601
  • [6] A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
    Igawa, S.
    Noro, R.
    Kubota, K.
    Naoki, K.
    Bessho, A.
    Hirose, T.
    Shimokawa, T.
    Nakashima, M.
    Minato, K.
    Seki, N.
    Tokito, T.
    Harada, T.
    Sasada, S.
    Miyamoto, S.
    Tanaka, Y.
    Furuya, N.
    Kaburagi, T.
    Hayashi, H.
    Lihara, H.
    Okamoto, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1399 - S1400
  • [7] A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
    Noro, R.
    Igawa, S.
    Bessho, A.
    Hirose, T.
    Tsuneo, S.
    Nakashima, M.
    MInato, K.
    Seki, N.
    Tokito, T.
    Harada, T.
    Sasada, S.
    Miyamoto, S.
    Tanaka, Y.
    Furuya, N.
    Kaburagi, T.
    Hayashi, H.
    Iihara, H.
    Naoki, K.
    Okamoto, H.
    Kubota, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S872 - S873
  • [8] A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR): Thoracic Oncology 1 Research Group (TORG) 0911
    Nakahara, Yoshiro
    Hosomi, Yukio
    Yamada, Kazuhiko
    Okamoto, Hiroaki
    Kato, Terufumi
    Komase, Yuko
    Nishikawa, Masanori
    Morita, Satoshi
    Kunitoh, Hideo
    Watanabe, Koshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911
    Yamada, Kazuhiko
    Aono, Hiromi
    Hosomi, Yukio
    Okamoto, Hiroaki
    Kato, Terufumi
    Komase, Yuko
    Nishikawa, Masanori
    Azuma, Koichi
    Takeoka, Hiroaki
    Okuma, Yusuke
    Nakahara, Yoshiro
    Sato, Akira
    Oba, Mari S.
    Morita, Satoshi
    Kunitoh, Hideo
    Watanabe, Koshiro
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (14) : 1904 - 1910
  • [10] ABCB1 genetic polymorphism and pharmacokinetic analysis of low dose erlotinib in frail patients with EGFR mutation (mt)-positive, non-small cell lung cancer: TORG1425
    Miyamoto, S.
    Tokkito, T.
    Bessho, A.
    Fukamatsu, N.
    Kunitoh, H.
    Ishii, M.
    Tanaka, H.
    Aono, H.
    Fukui, T.
    Kusaka, K.
    Hosomi, Y.
    Hamada, A.
    Yamada, K.
    Okamoto, H.
    ANNALS OF ONCOLOGY, 2018, 29
12345